Here’s what you need to know:
1. Kovanaze was approved by the FDA in June 2016.
2. Unlike standard dental anesthetic, which is administered through needle injection, Kovanaze is administered through a nasal spray.
3. Kovanaze is a topic, tooth nerve anesthetic containing tetracaineHCl (an ester local anesthetic) and oxymetazolineHCl (a vasoconstrictor).
4. The anesthetic is meant for restoratives procedures on Teeth 4 through 13 and A through J in adults and children who weigh more than 40 kilograms.
5. St. Renatus announced the launch of Kovanaze at the 2016 American Dental Association Meeting.
More articles on dental news:
Henry Schein to donate $50k to AAO’s Donated Orthodontic Services program: 3 notes
Patterson Dental enters distribution partnership with Heartland Dental: 3 notes
Community dental center for low-income seniors opens in San Diego: 5 notes